超越铂类衍生物的耳毒性。
Ototoxicity beyond platinum-based derivatives.
文献信息
| PMID | 42714591 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Cecília Vieira Peruch |
| 作者单位 | Graduate Program in Pathology, Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, Rio Grande do Sul, Brazil. |
| 期刊 | Cancer chemotherapy and pharmacology |
| SCI 分区 | Q3 |
| IF | 2.7 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 耳科 |
中文摘要
目的： 化疗引起的耳毒性是一个日益严重的问题。文献强调了铂类化合物的影响。然而，其他化疗药物也已证实可导致听力学改变。本研究旨在比较接受不同化疗方案的成年患者治疗前后畸变产物耳声发射（DPOAEs）的变化。
方法： 队列研究，纳入2022年4月至2023年12月期间接受化疗（CT）的174名个体。所有患者在开始化疗前和完成治疗后，均在2 kHz、4 kHz、6 kHz、8 kHz、10 kHz和12 kHz频率下进行DPOAE评估。为进行差异分析，将方案分为含铂类药物的化疗和其他方案。
结果： 79%的患者在DPOAE测试的至少一个频率上观察到反应下降。在接受不含铂类衍生物化疗的患者中，81%在治疗后检查中表现出改变，而在含铂类化合物组中，79%的受试者观察到改变。不同频率的反应恶化百分比分别为：2 kHz为27.6%，4 kHz为24.6%，6 kHz为41.2%，8 kHz为58.8%，10 kHz为57.4%，12 kHz为72.4%。含铂和不含铂的化疗方案的耳毒性效应在高频更为明显，组间无统计学显著差异。
结论： 在所研究的样本中，化疗通过DPOAEs的变化显示出耳毒性迹象。含铂和不含铂药物方案的耳毒性效应相似，凸显了对所有化疗患者进行听力学监测的必要性。
英文摘要
PURPOSE: Ototoxicity caused by chemotherapy is a growing problem. Literature highlights the effects of platinum compounds. However, other chemotherapy drugs also have demonstrated audiological changes. The objective of this study was to compare pre- and post-treatment distortion product otoacoustic emissions (DPOAEs) in adult patients undergoing different chemotherapy regimens.
METHODS: Cohort study comprising 174 individuals receiving chemotherapy (CT) between April 2022 and December 2023. DPOAE were evaluated in all patients at 2 kHz, 4 kHz, 6 kHz, 8 kHz, 10 kHz, and 12 kHz, before initiating chemotherapy and after completing the treatment. For differential analysis, the protocols were grouped into CT with platinum-based agents and other protocols.
RESULTS: A reduction in response in at least one frequency of the DPOAE test was observed in 79% of the patients. 81% of those who received CT without platinum derivatives exhibited alterations in post-treatment examinations, whereas in the group with platinum-based compounds, alterations were observed in 79% of the subjects. Different percentages of response deterioration were observed across frequencies: 27.6% at 2 kHz, 24.6% at 4 kHz, 41.2% at 6 kHz, 58.8% at 8 kHz, 57.4% at 10 kHz, and 72.4% at 12 kHz. The ototoxic effect of chemotherapy protocols, with and without platinum, was more pronounced at higher frequencies, with no statistically significant difference between the groups.
CONCLUSION: Chemotherapy has shown signs of ototoxicity through changes in DPOAEs in the sample studied. The ototoxic effects were similar between drug protocols with and without platinum, highlighting the need for audiological monitoring in all chemotherapy patients.